- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP1801h | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking Peptide - Product info | |
| Primary Accession | Q9H492 |
| Clone Names | 80317105 |
| Calculated MW | 14272 Da |
APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking Peptide - Additional info | |
| Gene ID 84557 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP1801h was selected from the MAP1LC3A region of human Phospho-APG8a (MAP1LC3A). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking Peptide - Protein Information | |
| Name MAP1LC3A | |
| Function Involved in formation of autophagosomal vacuoles (autophagosomes) | |
| Cellular Location Cytoplasm, cytoskeleton. Endomembrane system; Lipid-anchor. Cytoplasmic vesicle, autophagosome membrane; Lipid-anchor. Cytoplasmic vesicle, autophagosome. Note=LC3-II binds to the autophagic membranes | |
| Tissue Location Most abundant in heart, brain, liver, skeletal muscle and testis but absent in thymus and peripheral blood leukocytes | |
APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking Peptide - Related products
AM1823a: APG8a (MAP1LC3A)-S12 Antibody
AP1801a: LC3 Antibody (APG8A) (N-term)
AP1801b: LC3 Antibody (APG8A) (P45)
AP1801c: LC3 Antibody (APG8A) (I31)
AP1801d: LC3 Antibody (APG8A) (D106)
AP1801e: LC3 Antibody (APG8A) (S12)
AP1801f: LC3 Antibody (APG8A) (S3)
AP1801g: LC3 Antibody (APG8A) (T93/Y99)
AP1801h: LC3 Antibody (APG8A) (T93/Y99)
AP1801i: LC3 Antibody (Isoform B Specific)
AP1805a: Cleaved LC3A Antibody
AP3301a: Phospho-LC3C-S12 Antibody
AP3620a: Phospho-LC3A-T93 Antibody
AP3641a: Phospho-LC3A-S3 Antibody
AP3706a: Phospho-APG8a (MAP1LC3A)-Y99 Antibody
RI13150: MAP1LC3A predesign siRNA
BP1801a: LC3 Antibody (APG8a) (N-term) Blocking Peptide
BP1801b: LC3 (APG8a) Antibody (P45) Blocking Peptide
BP1801c: LC3 Antibody (APG8a) (I31) Blocking Peptide
BP1801d: LC3 Antibody (APG8a) (D106) Blocking Peptide
BP1801e: APG8a (MAP1LC3A) Antibody (S12) Blocking Peptide
BP1801f: APG8a (MAP1LC3A) Antibody (S3) Blocking Peptide
BP1801g: APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking Peptide
BP1801h: APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking Peptide
BP1801i: APG8a (MAP1LC3A) Antibody (Isoform b specific) Blocking Peptide
BP1805a: Cleaved-LC3 Antibody (APG8a) Blocking Peptide
BP3301a: Phospho-LC3 (APG8a) - S12 Antibody Blocking Peptide
BP3620a: Phospho-APG8a (MAP1LC3A)-pT93 Antibody Blocking Peptide
BP3641a: Phospho-APG8a (MAP1LC3A)-pS3 Antibody Blocking Peptide
BP3706a: Phospho-APG8a(MAP1LC3A)-Y99 Antibody Blocking Peptide
APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). MAP1A and MAP1B are microtubule-associated proteins which mediate the physical interactions between microtubules and components of the cytoskeleton. These proteins are involved in formation of autophagosomal vacuoles (autophagosomes). MAP1A and MAP1B each consist of a heavy chain subunit and multiple light chain subunits. MAP1LC3a is one of the light chain subunits and can associate with either MAP1A or MAP1B. The precursor molecule is cleaved by APG4B/ATG4B to form the cytosolic form, LC3-I. This is activated by APG7L/ATG7, transferred to ATG3 and conjugated to phospholipid to form the membrane-bound form, LC3-II.
REFERENCES
Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005) Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005) Greenberg JT. Dev Cell. 8(6):799-801. (2005) Levine B. Cell. 120(2):159-62. (2005) Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004)Tanida I., et al. Int. J. Biochem. Cell Biol. 36:2503-2518(2004)He H., et al. J. Biol. Chem. 278:29278-29287(2003) Tanida I., et al. J. Biol. Chem. 279:36268-36276(2004)